Serum cytokine profile in adalimumab-treated refractory uveitis patients: Decreased IL-22 correlates with clinical responses

Ocular Immunology and Inflammation

Volumn 21, Issue 3, 2013, Pages 212-219

  Cordero Coma, Miguel ^a   Calleja, Sara ^a   Llorente, Milagros ^a   Rodriguez, Esther ^a   Franco, Manuel ^a   Ruiz De Morales, Jose G ^a,b  

^a Complejo Asistencial Universitario de León   (Spain)

^b UNIVERSITY OF LEÓN   (Spain)

Author keywords

Adalimumab; Anti TNF; Cytokines; Interleukin 22; Serum; Uveitis

Indexed keywords

ADALIMUMAB; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P70; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 22; INTERLEUKIN 6; PROTEIN P70; STEROID; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; FOLLOW UP; HUMAN; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; UVEITIS;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; CHRONIC DISEASE; CYTOKINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS; YOUNG ADULT;

EID: 84878461045     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273948.2013.770888     Document Type: Article

References (34)

1. Whitcup S. (2010). Diagnostic testing. In: Nussenblatt R, Whitcup S. (eds.), Uveitis: Fundamentals and Clinical Practice, 4th ed. (pp. 60-71). New York: Mosby-Elsevier.
2. Tervo T, van Setten GB, Hovi M, et al. C-reactive protein serum levels in patients with ocular disease. Acta Ophthalmol (Copenh). 1994;72:110-113. (Pubitemid 24099193)
3. de Vries MK, van Eijk IC, van der Horst-Bruinsma IE, et al. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid A protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Rheum. 2009;61: 1484-1490.
4. Horai R, Caspi RR. Cytokines in autoimmune uveitis. J Interferon Cytokine Res. 2011;31:733-744.
5. Sugita S, Takase H, Taguchi C, Mochizuki M. The role of soluble TNF receptors for TNF-a in uveitis. Invest Ophthalmol Vis Sci. 2007;48:3246-3252. (Pubitemid 351261170)
6. Fine HF, Baffi J, Reed GF, et al. Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema. Am J Ophthalmol. 2001; 132:794-796. (Pubitemid 33031303)
7. Curnow SJ, Falciani F, Durrani OM, et al. Multiplex bead immunoassay analysis of aqueous humor reveals distinct cytokine profile in uveitis. Invest Ophthalmol Vis Sci. 2005; 46:4251-4259. (Pubitemid 44264629)
8. Pérez VL, Papaliodis GN, Chu D, et al. Elevated levels of interleukin 6 in the vitreous fluid of patients with pars planitis and posterior uveitis: the Massachusetts eye & ear experience and review of previous studies. Ocul Immunol Inflamm. 2004;12:193-201. (Pubitemid 39424882)
9. Sagawa K, Ito K, Sakaguchi M. Production of IL-8 and the other cytokines by T cell clones established from the ocular fluid of patients with Behcet's disease. Ocul Immunol Inflamm. 1995;3:63-71
10. el-Shabrawi Y, Livir-Rallatos C, Christen W, et al. High levels of interleukin-12 in aqueous and vitreous of patients with uveitis patients. Ophthalmology. 1998;105:1659-1663. (Pubitemid 28513517)
11. Kuiper JJ, Mutis T, de Jager W, et al. Intraocular interleukin-17 and proinflammatory cytokines in HLA-A29-associated birdshot chorioretinopathy. Am J Ophthalmol. 2011;152:177-182.
12. Kebir H, Kreymborg K, Ifergan I, et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med. 2007;13: 1173-1175. (Pubitemid 47530640)
13. Santos Lacomba M, Marcos Mart́in C, Gallardo Galera JM, et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res. 2001;33:251-255. (Pubitemid 34701624)
14. Kramer M, Monselise Y, Bahar I, et al. Serum cytokine levels in active uveitis and remission. Curr Eye Res. 2007;32: 669-675. (Pubitemid 47400689)
15. Klok AM, Luyendijk L, Zaal MJ, et al. Elevated serum IL-8 levels are associated with disease activity in idiopathic intermediate uveitis. Br J Ophthalmol. 1998;82:871-874. (Pubitemid 28408142)
16. Chi W, Zhu X, Yang P, et al. Upregulated IL-23 and IL-17 in Behçet patients with active uveitis. Invest Ophthalmol Vis Sci. 2008;49:3058-3064.
17. Li F, Yang P, Liu X, et al. Upregulation of interleukin 21 and promotion of interleukin 17 production in chronic or recurrent Vogt-Koyanagi-Harada disease. Arch Ophthalmol. 2010;128:1449-1454.
18. Jiang S, Liu X, Luo L, et al. Elevated serum IL-23 correlates with intraocular inflammation after cataract surgery in patients with Vogt-Koyanagi-Harada disease. Br J Ophthalmol. 2010;94:1078-1082.
19. Takase H, Futagami Y, Yoshida T, et al. Cytokine profile in aqueous humor and sera of patients with infectious or noninfectious uveitis. Invest Ophthalmol Vis Sci. 2006;47: 15557-1561.
20. Dick AD, Forrester JV, Liversidge J, et al. Role of TNFa in experimental autoimmune uveitis. Prog Retin Eye Res. 2004; 23:617-637.
21. Sharma SM, Nestel AR, Lee RW, Dick AD. Clinical review: anti-TNF-alpha therapies in uveitis: perspective on 5 years of clinical experience. Ocul Immunol Inflamm. 2009;17: 403-414.
22. Suhler EB, Smith JR, Giles TR, et al. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol. 2009;127:819-822.
23. Sugita S, Yamada Y, Kaneko S, et al. Induction of regulatory T cells by infliximab in Behçet's disease. Invest Ophthalmol Vis Sci. 2011;52:476-484.
24. Calleja S, Cordero-Coma M, Rodriguez E, et al. Adalimumab specifically induces CD3(+) CD4(+) CD25(high) Foxp3(+) CD127(-) T-regulatory cells and decreases vascular endothelial growth factor plasma levels in refractory immuno-mediated uveitis: a nonrandomized pilot intervention study. Eye (Lond). 2012;26: 468-477.
25. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol. 2005; 140:509-516. (Pubitemid 41224845)
26. Charles P, Elliot MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF alpha therapy in rheumatoid arthritis. J Immunol. 1999;163:1521-1528. (Pubitemid 29352775)
27. Mastroianni A, Minutilli E, Mussi A, et al. Cytokine profiles during infliximab monotherapy in psoriatic arthritis. Br J Dermatol. 2005;153:531-536. (Pubitemid 41248208)
28. Martinez-Borra J, Lopez-Larrea C, Gonzalez S, et al. High serum tumor necrosis factor alfa levels are associated with lack of response to infliximab in fistulizing Crohn's disease. Gastroenterology. 2002;97:2350-2356.
29. Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor a blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheumatism. 2004;50:3161-3169. (Pubitemid 39371992)
30. Caproni M, Antiga E, Melani L, et al. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol. 2009;29:210-214.
31. da Rocha Jr LF, Duarte AL, Dantas AT, et al. Increased serum interleukin 22 in patients with rheumatoid arthritis and correlation with disease activity. J Rheumatol. 2012;39: 1320-1325.
32. Ke Y, Sun D, Jiang G, et al. IL-22-induced regulatory CD11b APC suppress experimental autoimmune uveitis. J Immunol. 2011;187:2130-2139.
33. Li Z, Liu B, Maminishkis A, et al. Gene expression profiling in autoimmune noninfectious uveitis disease. J Immunol. 2008;181:5147-5157.
34. Liang SC, Nickerson-Nutter C, Pittman DD, et al. IL-22 induces an acute-phase response. J Immunol. 2010;185: 5531-5538.